Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of QLS1410 in uncontrolled hypertension on background antihypertensive therapy
CTR20263996Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of QLS1410 in hypertension (HTN), resistant hypertension (RH), sponsored by Qilu Pharmaceutical. Started Oct 2026; status: active.
02
Drugs
QLS1410
03
Conditions
hypertension (HTN)resistant hypertension (RH)
Beyond the preview
Go deeper on CTR20263996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263996.